6533b82efe1ef96bd1293e1f
RESEARCH PRODUCT
Small, dense LDL: An update
Manfredi RizzoPhilipp A. GerberDragana Nikolicsubject
cardiovascular riskmedicine.medical_specialtySmall dense ldl10265 Clinic for Endocrinology and Diabetology030209 endocrinology & metabolism610 Medicine & health030204 cardiovascular system & hematology2705 Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusCardiovascular DiseaseMedicineHumansParticle SizeMetabolic Syndromebusiness.industryCholesterollipid-lowering therapieBiomarkerCholesterol LDLmedicine.diseaseAtherosclerosisObesityEndocrinologychemistrysmall dense LDLs: AtherosclerosiCardiovascular DiseasesCardiology and Cardiovascular MedicinebusinessBiomarkersdescription
Purpose of review In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including their associations with other biomarkers. Recent findings Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes, obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic agents and nutraceuticals, exert favourable effects on these atherogenic particles. The 'gold standard' methodology for the assessment of sdLDL has not been established yet. However, the association between sdLDL and several biomarkers could facilitate their assessment. Summary Estimation of sdLDL in daily clinical practice may help with the identification of patients at high cardiovascular risk and further contribute in directing specific interventions to prevent and/or decrease such risk.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-07-01 |